A Study of ZL-1310 in Participants With Selected Solid Tumors
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
| Condition(s) | Solid Tumors |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors |
| Who can participate | Inclusion Criteria: * Signed informed consent * Adult men and women ≥18 years of age * Participants must have histologically confirmed, locally advanced or metastatic NeuroEndocrine Carcionomas (NEC), and must have experienced disease progression on or after platinum-based therapy * Participants must be willing to undergo a tumor biopsy or must provide archived tumor tissue sample * Participants must have at least one measurable target lesion as defined by RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy ≥ 3 months Exclusion Criteria: * Participants with another known malignancy that is progressing or requires active treatment within the last 2 years * Clinically active central nervous system (CNS) metastases * Participants with leptome |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Zai Lab (Shanghai) Co., Ltd. |
| Locations | San Francisco, California, United States; Peoria, Illinois, United States; Detroit, Michigan, United States; New York, New York, United States; Cleveland, Ohio, United States; Philadelphia, Pennsylvania, United States (+15 more sites) |
| Start date | 2025-05-12 |
| NCT ID | NCT06885281 |
| Official listing | https://clinicaltrials.gov/study/NCT06885281 |